Brainstorm expands clinical pipeline to evaluate nurown for treatment of alzheimer's disease

Brainstorm expands clinical pipeline to evaluate nurown for the treatment of alzheimer's disease.brainstorm cell therapeutics - protocol for proposed multi-national trial has been submitted for eu regulatory approval.brainstorm cell therapeutics - phase 2 trial to evaluate safety & efficacy of nurown treatment in those with prodromal to mild alzheimer's disease.
BCLI Ratings Summary
BCLI Quant Ranking